Noura H Abd Ellah1,2, Esraa A Ahmed3, Rasha B Abd-Ellatief3, Marwa F Ali4, Asmaa M Zahran5, Helal F Hetta6,7. 1. Division of Pharmaceutical Sciences, James L Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA. 2. Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt. 3. Department of Pharmacology, Faculty of Medicine, Assiut University, Assiut 71515, Egypt. 4. Department of Pathology and Clinical Pathology, Faculty of Veterinary Medicine, Assiut University, Assiut 71515, Egypt. 5. Department of Clinical Pathology, South Egypt Cancer Institute, Assiut, Egypt. 6. Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0595, USA, helal.hetta@uc.edu. 7. Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut 71526, Egypt, helal.hetta@uc.edu.
Abstract
BACKGROUND: The inflammatory basis of diabetes mellitus directed the researchers' attention to the immune system for better management and prevention of complications. Metoclopramide (MCA; the only US Food and Drug Administration-approved for gastroparesis) has the ability to restore immune function through increasing prolactin secretion. This study aimed to test the effect of BSA/MCA nanoparticles (NPs) on modulating immune response. METHODS: BSA/MCA NPs were fabricated by desolvation and evaluated in vitro via measuring loading efficiency, particle size, and surface charge. The selected formula was further evaluated via differential scanning calorimetry and release behavior. Then, NPs were injected into rats (25 mg MCA/kg/week) for 3 weeks to be evaluated histopathologically and immunologically via measuring proinflammatory cytokines, such as IL1β, IL6, and TNFα, in addition to measuring regulatory T-cell frequency. RESULTS: MCA was successfully loaded on BSA, achieving high encapsulation efficiency reaching 63±2%, particles size of 120-130 nm with good polydispersity, and a negative surface charge indicating that entire positively charged drug was encapsulated inside NPs. Differential scanning calorimetry thermography of selected NPs showed an obvious interaction between components and cross-linking of BSA molecules using glutaraldehyde, resulting in sustained release of MCA (around 50% within 3 days). MCA NPs significantly restored the immune response via decreasing proinflammatory cytokines and increasing regulatory T-cell frequency when compared to control and free MCA (drug not loaded in NPs)-treated groups. Histopathological examination of this MCA NPs-treated group did not show the characteristic lesions of diabetes, and apoptosis nearly disappeared. CONCLUSION: BSA/MCA NPs could be considered a new modality for treatment of gastro-paresis, in addition to management of diabetes itself and preventing its complications via an MCA-immunomodulatory effect.
BACKGROUND: The inflammatory basis of diabetes mellitus directed the researchers' attention to the immune system for better management and prevention of complications. Metoclopramide (MCA; the only US Food and Drug Administration-approved for gastroparesis) has the ability to restore immune function through increasing prolactin secretion. This study aimed to test the effect of BSA/MCA nanoparticles (NPs) on modulating immune response. METHODS: BSA/MCA NPs were fabricated by desolvation and evaluated in vitro via measuring loading efficiency, particle size, and surface charge. The selected formula was further evaluated via differential scanning calorimetry and release behavior. Then, NPs were injected into rats (25 mg MCA/kg/week) for 3 weeks to be evaluated histopathologically and immunologically via measuring proinflammatory cytokines, such as IL1β, IL6, and TNFα, in addition to measuring regulatory T-cell frequency. RESULTS: MCA was successfully loaded on BSA, achieving high encapsulation efficiency reaching 63±2%, particles size of 120-130 nm with good polydispersity, and a negative surface charge indicating that entire positively charged drug was encapsulated inside NPs. Differential scanning calorimetry thermography of selected NPs showed an obvious interaction between components and cross-linking of BSA molecules using glutaraldehyde, resulting in sustained release of MCA (around 50% within 3 days). MCA NPs significantly restored the immune response via decreasing proinflammatory cytokines and increasing regulatory T-cell frequency when compared to control and free MCA (drug not loaded in NPs)-treated groups. Histopathological examination of this MCA NPs-treated group did not show the characteristic lesions of diabetes, and apoptosis nearly disappeared. CONCLUSION: BSA/MCA NPs could be considered a new modality for treatment of gastro-paresis, in addition to management of diabetes itself and preventing its complications via an MCA-immunomodulatory effect.
Authors: D Jarrar; P Wang; G Y Song; M W Knöferl; W G Cioffi; K I Bland; I H Chaudry Journal: Am J Physiol Endocrinol Metab Date: 2000-01 Impact factor: 4.310
Authors: Kathrin Maedler; Pavel Sergeev; Frédéric Ris; José Oberholzer; Helen I Joller-Jemelka; Giatgen A Spinas; Nurit Kaiser; Philippe A Halban; Marc Y Donath Journal: J Clin Invest Date: 2002-09 Impact factor: 14.808
Authors: R Oberbeck; D Schmitz; K Wilsenack; M Schüler; B Pehle; M Schedlowski; M S Exton Journal: Eur Surg Res Date: 2004 Mar-Apr Impact factor: 1.745
Authors: Fatma R Khalaf; Heba M Fahmy; Ahmed K Ibrahim; Ghada A Mohamed; Manal El Sayed Ez Eldeen; Azza Elkady; Helal F Hetta Journal: Diabetes Metab Syndr Obes Date: 2019-09-20 Impact factor: 3.168
Authors: Usama H Abo-Shama; Hanem El-Gendy; Walid S Mousa; Ragaa A Hamouda; Wesam E Yousuf; Helal F Hetta; Eman E Abdeen Journal: Infect Drug Resist Date: 2020-02-07 Impact factor: 4.003
Authors: Helal F Hetta; Israa M S Al-Kadmy; Saba Saadoon Khazaal; Suhad Abbas; Ahmed Suhail; Mohamed A El-Mokhtar; Noura H Abd Ellah; Esraa A Ahmed; Rasha B Abd-Ellatief; Eman A El-Masry; Gaber El-Saber Batiha; Azza A Elkady; Nahed A Mohamed; Abdelazeem M Algammal Journal: Sci Rep Date: 2021-05-24 Impact factor: 4.379